Nimble Therapeutics has expanded its collaboration and executed a license agreement with Genentech, the company announced recently.

According to a release, the two companies will work together on the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas. Nimble will apply its platform against multiple targets, and Genentech will be responsible for the preclinical and clinical development and commercialization of any resulting products.

“We are excited to significantly expand our partnership and strengthen our collaboration with Genentech,” Nimble Therapeutics CEO Jigar Patel said in a statement. “Genentech has been a valuable strategic partner, and we are proud that our success thus far has led to the opportunity to significantly broaden our work together with both Genentech and Roche.”

Under the terms of the agreement, Nimble will receive a $20 million upfront payment as well as tiered royalties.